Openbookopenbook
Equity
Smith & Nephew PLC(SN)
GBX --+0.00%
Reward70High
Risk26Low
📊75%Data
3.0% dividend yield
SN
+0.0 · +0.00%
GBX · LSE
Smith & Nephew PLC | Healthcare
Quality Compounder
Market Cap:11.55Bn
ℹ️
Reward Rating
70
High
Top 25% (model universe)
75% data coverage
ℹ️
Risk Rating
26
Low
Risk Assessment
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on SN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: 1427p.

What is Smith & Nephew PLC?

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.

SN · Verdict

Strong reward · low risk

SN scores well on cash flow and valuation with no major weaknesses flagged in the model.

Based on 88% data coverage

SN · Verdict

What’s working & what to watch

Strengths 6

  • Cash flow86/100

    14% free-cash-flow margin

  • Valuation84/100

    P/E 13.0× · PEG 0.68

  • Profitability80/100

    10% net margin · 12% ROE

  • Growth71/100

    Rev +6.5% CAGR · earnings +42.0%

  • Balance sheet68/100

    Interest covered 6.4×

  • Volatility65/100

    Above average

No major weaknesses flagged.

Model-based scoring. For information only — not financial advice.

What is Smith & Nephew PLC?

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company is listed on the LSE in UK, operating in the Healthcare sector, with a market capitalisation of 11.55B, and a P/E ratio of 32.4x.

Financial Highlights

Investment Breakdown

📈 Growth
Revenue and earnings growing steadily, indicating improving operating performance.
💰 Profitability
Strong margins and consistent earnings support financial stability.
⚠️ Risk
Below-average volatility supports a steadier risk profile.
💸 Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (70)

The scoring profile indicates a strong reward potential, driven primarily by valuation and profitability. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap11.55B
P/E Ratio32.381
Dividend Yield2.98%
52 Week High1429.5167
52 Week Low930.0039
Last AnnualDecember
IPO Date11/16/1999
IncorporatedUK
Shares Outstanding849M
No. of Employees17,000
IndustryMedical Devices
ExchangeLSE
Beta0.684
CurrencyGBX
Websitewww.smith-nephew.com
openbook

Stock research for everyday UK investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.